Mylan CEO Regrets Patient Blowback, But Not Expanded EpiPen Use
- CEO Heather Bresch to testify before House committee Wednesday
- Congress has raised concern over price hikes of EpiPen
Heather Bresch
Photographer: Michael Nagle/BloombergThis article is for subscribers only.
Mylan NV’s chief executive officer will tell Congress Wednesday that although she regrets some patients’ financial difficulties affording the EpiPen allergy shot, lawmakers should still recognize that the company has increased access to the drug.
CEO Heather Bresch will testify before the U.S. House Committee on Oversight and Government Reform and face questions from lawmakers about how the company raised the cost to about $600 for a two-pack, from $57 a shot when Mylan acquired the rights to sell the product in 2007.